{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:07:33Z","timestamp":1787170053091,"version":"build-2736575974"},"reference-count":34,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T00:00:00Z","timestamp":1702857600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Cytomegalovirus (CMV) infection is a relevant cause of morbimortality in patients receiving allogeneic stem cell transplantation (allo-HCT). Foscarnet (FCN) is an effective drug against CMV administered intravenously and usually on an inpatient basis. The Home Care Unit (HCU) for hematologic patients at our hospital designed an at-home FCN administration model to avoid the hospitalization of patients requiring FCN treatment. This study analyzes whether the at-home administration of FCN is as safe and effective as its hospital administration. We collected and compared demographic, clinical, analytical, and economic data of patients with CMV infection post-allo-HCT who received FCN in the hospital (n = 16, 17 episodes) vs. at-home (n = 67, 88 episodes). The proportions of patients with cured CMV infections were comparable between the two groups (65.9% vs. 76.5%, p = 0.395). The median duration of FCN treatment was 15 (interquartile range [IQR] 9\u201323) and 14 (IQR 11\u201319) days in the HCU and inpatient cohorts, respectively (p = 0.692). There were no significant differences in the FCN toxicities between groups except for hypocalcemia (26.1% vs. 58.8%, p = 0.007), which was more prevalent in the inpatient cohort. A significant cost-effectiveness was found in the HCU cohort, with a median savings per episode of EUR 5270. It may be concluded that home administration of FCN is a safe, effective, and cost-efficient therapeutic option for patients with CMV infection and disease.<\/jats:p>","DOI":"10.3390\/ph16121741","type":"journal-article","created":{"date-parts":[[2023,12,18]],"date-time":"2023-12-18T05:41:35Z","timestamp":1702878095000},"page":"1741","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["At-Home Foscarnet Administration in Patients with Cytomegalovirus Infection Post-Allogeneic Stem Cell Transplantation: A Unicentric, Safe, and Feasible Program"],"prefix":"10.3390","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9956-1745","authenticated-orcid":false,"given":"Sonia","family":"Ruiz-Boy","sequence":"first","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Pedraza","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"},{"name":"Blood Bank Department, Biomedical Diagnostic Center, Blood and Tissue Bank, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Prat","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4567-3682","authenticated-orcid":false,"given":"Maria Queralt","family":"Salas","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther","family":"Carcelero","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8259-0811","authenticated-orcid":false,"given":"Gisela","family":"Riu-Viladoms","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda","family":"Su\u00e1rez-Lled\u00f3","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Monge-Escart\u00edn","sequence":"additional","affiliation":[{"name":"Pharmacy Service, Division of Medicines, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Gerardo","family":"Rodr\u00edguez-Lobato","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2143-5356","authenticated-orcid":false,"given":"Alexandra","family":"Mart\u00ednez-Roca","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"},{"name":"Home Care and Bone Marrow Transplantation Unit, Department of Hematology, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Rovira","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmen","family":"Mart\u00ednez","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Gallego","sequence":"additional","affiliation":[{"name":"Home Care and Bone Marrow Transplantation Unit, Department of Hematology, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1lvaro","family":"Urbano-Ispizua","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Financial-Economic Department, Institute of Cancer and Blood Diseases Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda \u00c1ngeles","family":"Marcos","sequence":"additional","affiliation":[{"name":"Microbiology Department, Hospital Cl\u00ednic de Barcelona, University of Barcelona, ISGlobal, CIBERINFEC (Centro de Investigaci\u00f3n Biom\u00e9dica En Red enfermedades INFECciosas), 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesc","family":"Fern\u00e1ndez-Avil\u00e9s","sequence":"additional","affiliation":[{"name":"Hematopoietic Stem Cell Transplantation Unit, Hematology Department, Institute of Cancer and Blood Diseases, Hospital Cl\u00ednic de Barcelona, IDIBAPS (Institut De Investigacions Biom\u00e8diques August Pi i Sunyer), Josep Carreras Institute, 08036 Barcelona, Spain"},{"name":"Home Care and Bone Marrow Transplantation Unit, Department of Hematology, Hospital Cl\u00ednic de Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,12,18]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e260","DOI":"10.1016\/S1473-3099(19)30107-0","article-title":"Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7)","volume":"19","author":"Ljungman","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/j.jtct.2021.09.010","article-title":"American Society for Transplantation and Cellular Therapy Series: #4\u2014Cytomegalovirus treatment and management of resistant or refractory infections after hematopoietic cell transplantation","volume":"27","author":"Yong","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Cho, S.Y., Lee, D.G., and Kim, H.J. (2019). Cytomegalovirus Infections after Hematopoietic Stem Cell Transplantation: Current Status and Future Immunotherapy. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20112666"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1093\/cid\/ciw668","article-title":"Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials","volume":"64","author":"Ljungman","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Ouellette, C.P. (2022). Adoptive Immunotherapy for Prophylaxis and Treatment of Cytomegalovirus Infection. Viruses, 14.","DOI":"10.3390\/v14112370"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1080\/14740338.2019.1662787","article-title":"Safety considerations with current and emerging antiviral therapies for cytomegalovirus infection in transplantation","volume":"18","author":"Razonable","year":"2019","journal-title":"Expert. Opin. Drug Saf."},{"key":"ref_7","unstructured":"European Medicines Agency (2023, January 15). European Public Assessment Report (EPAR): Foscarnet. Summary of Products Characteristics. Available online: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/foscan-epar-product-information_en.pdf."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"e74","DOI":"10.1097\/TP.0000000000001418","article-title":"Outcomes in Transplant Recipients Treated with Foscarnet for Ganciclovir-Resistant or Refractory Cytomegalovirus Infection","volume":"100","author":"Avery","year":"2016","journal-title":"Transplantation"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4855","DOI":"10.1200\/JCO.2006.06.4238","article-title":"Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies","volume":"24","author":"Carreras","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1038\/s41409-019-0768-x","article-title":"A reproducible and safe at-home allogeneic haematopoietic cell transplant program: First experience in Central and Southern Europe","volume":"55","author":"Rovira","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1080\/10428194.2020.1742901","article-title":"Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients","volume":"61","author":"Moreno","year":"2020","journal-title":"Leuk. Lymphoma"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Gonz\u00e1lez, M.J., Urizar, E., Urtaran-Laresgoiti, M., Nu\u00f1o-Solin\u00eds, R., L\u00e1zaro-P\u00e9rez, E., V\u00e1zquez, L., Pascual-Casc\u00f3n, M.J., Solano, C., Kown, M., and Gallego, C. (2021). Hospital and outpatient models for Hematopoietic Stem Cell Transplantation: A systematic review of comparative studies for health outcomes, experience of care and costs. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0254135"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/S0140-6736(88)92920-0","article-title":"Foscarnet infusion at home","volume":"2","author":"Heley","year":"1988","journal-title":"Lancet"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/S0140-6736(89)91167-7","article-title":"Foscarnet infusion at home","volume":"1","author":"Wood","year":"1989","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"622.e1","DOI":"10.1016\/j.jtct.2021.03.018","article-title":"Continuous-Infusion Foscarnet Facilitates Administration in Hematopoietic Stem Cell Transplantation Patients","volume":"27","author":"Domingo","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"342.e1","DOI":"10.1016\/j.jtct.2020.12.012","article-title":"Comparison of Transplantation Outcomes after Foscarnet and Ganciclovir Administration as First-Line Anti-Cytomegalovirus Preemptive Therapy","volume":"274","author":"Miyao","year":"2021","journal-title":"Transplant. Cell. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e157","DOI":"10.1016\/S2352-3026(19)30256-X","article-title":"Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: Updated consensus recommendations of the European Society for Blood and Marrow Transplantation","volume":"7","author":"Penack","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1182\/blood.2019001212","article-title":"Selection of unrelated donors and cord blood units for hematopoietic cell transplantation: Guidelines from the NMDP\/CIBMTR","volume":"134","author":"Dehn","year":"2019","journal-title":"Blood"},{"key":"ref_19","first-page":"CD001917","article-title":"Home versus hospital intravenous antibiotic therapy for cystic fibrosis","volume":"12","author":"Balaguer","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/S1473-3099(18)30729-1","article-title":"Efficacy and safety of intravenous ceftriaxone at home versus intravenous flucloxacillin in hospital for children with cellulitis (CHOICE): A single-centre, open-label, randomised, controlled, non-inferiority trial","volume":"19","author":"Ibrahim","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S0163-4453(03)00135-X","article-title":"A randomized trial of home vs hospital intravenous antibiotic therapy in adults with infectious diseases","volume":"48","author":"Wolter","year":"2004","journal-title":"J. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"e45","DOI":"10.1016\/S1473-3099(17)30345-6","article-title":"Inpatient versus outpatient parenteral antibiotic therapy at home for acute infections in children: A systematic review","volume":"18","author":"Bryant","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"106555","DOI":"10.1016\/j.ijantimicag.2022.106555","article-title":"Efficacy and safety of home-based intravenous antibiotic therapy among adults: A systematic review","volume":"59","author":"Pacheco","year":"2022","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1080\/1120009X.2021.1915074","article-title":"Relationship between renal dysfunction and electrolyte abnormalities in hematopoietic stem cell transplant patients treated with foscarnet","volume":"33","author":"Ota","year":"2021","journal-title":"J. Chemother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.bbmt.2020.03.019","article-title":"Impact of Preemptive Therapy for Cytomegalovirus on Toxicities after Allogeneic Hematopoietic Cell Transplantation in Clinical Practice: A Retrospective Single-Center Cohort Study","volume":"26","author":"Zavras","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_26","first-page":"141","article-title":"BK Virus Infections and Hemorrhagic Cystitis in Allogeneic Hematopoietic Stem Cell Transplant Recipients","volume":"46","author":"Alantake","year":"2023","journal-title":"New Microbiol."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Prezioso, C., and Pietropaolo, V. (2021). BK Virus and Transplantation. Viruses, 13.","DOI":"10.3390\/v13050733"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"512","DOI":"10.5694\/mja12.10480","article-title":"A meta-analysis of \u201chospital in the home\u201d","volume":"197","author":"Caplan","year":"2012","journal-title":"Med. J. Aust."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1146\/annurev-med-042921-124739","article-title":"Cytomegalovirus Therapy: Role of Letermovir in Prophylaxis and Treatment in Transplant Recipients","volume":"74","author":"Saullo","year":"2023","journal-title":"Annu. Rev. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/FTD.0000000000000925","article-title":"Therapeutic Drug Monitoring of Ganciclovir: Where Are We?","volume":"44","author":"Edwina","year":"2022","journal-title":"Ther. Drug Monit."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.cmi.2022.07.001","article-title":"Cytomegalovirus infection in transplant recipients: Newly approved additions to our armamentarium","volume":"29","author":"Khawaja","year":"2023","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: Synopsis of the kidney disease: Improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann. Intern. Med."},{"key":"ref_33","first-page":"1","article-title":"Kidney disease: Improving global outcomes (KDIGO) acute kidney injury work group. KDIGO clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"ref_34","unstructured":"National Institutes of Health, National Cancer Institute (2023, February 20). Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0, Available online: https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_8.5x11.pdf."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/12\/1741\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T21:40:45Z","timestamp":1760132445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/16\/12\/1741"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,18]]},"references-count":34,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["ph16121741"],"URL":"https:\/\/doi.org\/10.3390\/ph16121741","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,18]]}}}